Budesonide Inhalant
Product Images NDC 69097-321

21 FDA label images from Cipla Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 69097-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Struc-form-1 (Picture 1)

Struc-form-1 (Picture 1)
Chemical structure of Budesonide, the active ingredient in Budesonide Inhalation Suspension, as shown in the diagram. The structure includes detailed molecular bonds and groups characteristic of Budesonide's corticosteroid framework.*
FDA Label Image

Studies-1 (Picture 2)

Studies-1 (Picture 2)
Line graph depicting the mean change from baseline in nighttime asthma symptoms over 12 weeks for Budesonide Inhalation Suspension at doses 0.25 mg, 0.5 mg, and 1.0 mg once daily compared to placebo. The graph shows symptom improvement trends over time for each dose and placebo group.*
FDA Label Image

Graph-3 (Picture 3)

Graph-3 (Picture 3)
A line graph depicting mean change from baseline nighttime asthma symptoms over a 12-week period. The x-axis represents time intervals from baseline through weeks 0-12, and the y-axis shows mean change values ranging from -0.6 to 0.1. Three lines represent different dosing regimens: 0.25 mg twice daily, 0.5 mg twice daily, and 0.5 mg once daily, illustrating symptom changes over time for each dosing group.*
FDA Label Image

Graph-4 (Picture 4)

Graph-4 (Picture 4)
A line graph showing the mean change from baseline in nighttime asthma symptoms over a 12-week period. The graph compares five groups: placebo, 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1.0 mg once daily of Budesonide Inhalation Suspension. The vertical axis represents the mean change from baseline, while the horizontal axis represents different time intervals up to week 12.*
FDA Label Image

Image (87894b75 A8c5 4d48 81bd 5ad43d66afc3 797 2)

Image (87894b75 A8c5 4d48 81bd 5ad43d66afc3 797 2)
An instructional illustration depicting the removal of a plastic ampule from a foil pouch, showing a hand gripping the ampule by the top, as the first step in preparing the Budesonide Inhalation Suspension inhalant for use.*
FDA Label Image

Image (87894b75 A8c5 4d48 81bd 5ad43d66afc3 797 3)

Image (87894b75 A8c5 4d48 81bd 5ad43d66afc3 797 3)
An instructional illustration showing hands opening or separating a small plastic vial from a strip of four connected vials, likely representing single-dose units of an inhalation suspension product.*
FDA Label Image

Figure 2 (87894b75 A8c5 4d48 81bd 5ad43d66afc3 05)

Figure 2 (87894b75 A8c5 4d48 81bd 5ad43d66afc3 05)
An instructional illustration showing a hand holding a small vial with a flip-top cap being opened by lifting the top tab. The vial is positioned above a circular holder, with an arrow indicating a twisting motion to open or prepare the vial for use. This image relates to the handling or preparation of the Budesonide Inhalation Suspension inhalant.*
FDA Label Image

Figure 3 (87894b75 A8c5 4d48 81bd 5ad43d66afc3 06)

Figure 3 (87894b75 A8c5 4d48 81bd 5ad43d66afc3 06)
An instructional illustration showing two hands opening a small vial or ampule by snapping off the top at the scored neck. The image is a step labeled as step 3 in a sequence, likely demonstrating how to prepare Budesonide Inhalation Suspension for administration.*
FDA Label Image

Figure 4 (87894b75 A8c5 4d48 81bd 5ad43d66afc3 07)

Figure 4 (87894b75 A8c5 4d48 81bd 5ad43d66afc3 07)
An instructional illustration showing a person holding an inhalation device in one hand while using the other hand to insert or adjust the Budesonide Inhalation Suspension container into the device, demonstrating part of the preparation or assembly process.*
FDA Label Image

Pouch Label 0.25 (0pt25mgsingledose)

Pouch Label 0.25 (0pt25mgsingledose)
Label for Budesonide Inhalation Suspension 0.25 mg/2 mL by Cipla USA Inc. It is an oral inhalant indicated for inhalation only, supplied as single-dose ampules each containing 2 mL of sterile suspension. Dosage instructions, storage conditions at 20° to 25°C, and handling precautions including keeping ampules upright and protected from light are included. The label also shows the NDC 69097-318-32 and lot/expiration placeholders.*
FDA Label Image

Carton 0.25 (Carton0pt25)

Carton 0.25 (Carton0pt25)
Packaging label for Budesonide Inhalation Suspension 0.25 mg/2 mL oral inhalant by Cipla USA Inc. The label indicates it is a prescription drug to be used by inhalation only. The packaging includes instructions to store upright and shows the product is supplied as 30 single-dose ampules of 2 mL each. The label also features the Cipla logo and NDC number 69097-318-50.*
FDA Label Image

0.5 mg Pouch Label (0p5pouchlabel)

0.5 mg Pouch Label (0p5pouchlabel)
Label for Budesonide Inhalation Suspension 0.5 mg/2 mL oral inhalant by Cipla USA Inc. Displays dosing information, storage instructions, and package contents of one single-dose 2 mL ampule. Includes barcode, lot and expiration placeholders, and manufacturer details.*
FDA Label Image

0.5 mg Carton (0pt5carton)

0.5 mg Carton (0pt5carton)
Packaging label for Budesonide Inhalation Suspension 0.5 mg/2 mL by Cipla USA Inc. The label displays the product's dosage form as an inhalant for oral use and includes instructions to store upright and dispense from the top. The label shows the NDC code 0597-319-63, indicates it is Rx only, and mentions that the product contains 8 single-dose ampules of 2 mL each in a foil pouch.*
FDA Label Image

1 mg Pouch Label (1mgpouch)

1 mg Pouch Label (1mgpouch)
Label for Budesonide Inhalation Suspension 1 mg/2 mL oral inhalant by Cipla USA Inc. The label provides dosage form, strength, storage instructions, and usage directions. It includes warnings for inhalation use only, controlled room temperature storage, and single-dose ampule packaging details.*
FDA Label Image

1 mg Carton Label (1mgcarton)

1 mg Carton Label (1mgcarton)
Packaging label for Budesonide Inhalation Suspension 1 mg/2 mL oral inhalant by Cipla USA Inc. The label includes dosage strength, route (oral inhalation), storage instructions, and packaging details for a box containing 30 unit-dose ampules of 2 mL each.*
FDA Label Image

0.25 mg Label (0pt25label)

0.25 mg Label (0pt25label)
Label for Budesonide Inhalation Suspension 0.25 mg/2 mL, oral inhalant. The packaging specifies single-dose ampules, with 1 envelope containing five 2 mL ampules. Manufactured by Cipla Ltd. and labeled for Cipla USA Inc. It includes storage instructions, usage directions, and regulatory information.*
FDA Label Image

0pt25-indore-carton (Cartonindore0pt25)

0pt25-indore-carton (Cartonindore0pt25)
Packaging label for Budesonide Inhalation Suspension 0.25 mg/2 mL oral inhalant by Cipla USA Inc. The label displays product name, strength, dosage form, and instructions for use including graphical steps. It notes 30 single-dose ampules per carton with storage instructions to keep upright and that the product is for inhalation only.*
FDA Label Image

0.5 mg Label 1scount (0pt5label)

0.5 mg Label 1scount (0pt5label)
The packaging label of Budesonide Inhalation Suspension 0.5 mg/2 mL by Cipla USA Inc. It is an oral inhalant for human prescription use. The label states each ampule delivers 2 mL of a sterile suspension, supplied as 1 envelope containing five 2 mL single-dose ampules. Instructions include storage at 20 to 26°C, use only in a jet nebulizer, and disposal warnings. The label also displays the NDC code 69097-319-86 and the manufacturer's address.*
FDA Label Image

Indore-carton-0pt5 (Cartonindore 0pt5)

Indore-carton-0pt5 (Cartonindore 0pt5)
Budesonide Inhalation Suspension 0.5 mg/2 mL carton label from Cipla USA Inc. The label displays the product name, strength, dosage form, and instructions stating "For inhalation only" and "Store upright." It indicates a 30 single-dose ampoule per carton package and includes usage instructions with illustrations. The label also shows the NDC 69097-319-87 and a barcode.*
FDA Label Image

1 mg Label 5s Count (1mglabel5scount)

1 mg Label 5s Count (1mglabel5scount)
Label for Budesonide Inhalation Suspension 1 mg/2 mL oral inhalant, packaged as 1 envelope containing five 2 mL single-dose ampules. The label indicates it is for inhalation only, includes dosing and storage instructions, and is manufactured by Cipla USA Inc. The NDC number 69097-321-86 is shown along with handling precautions and directions.*
FDA Label Image

Indore-carton-1mg (Cartonindore 1mg)

Indore-carton-1mg (Cartonindore 1mg)
Packaging label for Budesonide Inhalation Suspension 1 mg/2 mL oral inhalant by Cipla USA Inc. The label indicates 30 single-dose ampules per carton and provides usage instructions with illustrations. Storage instructions specify to store upright, and the product is for inhalation only. The NDC is 69097-321-87.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.